重组人内抑素对佐剂性关节炎大鼠成纤维样滑膜细胞作用机制的研究
|
摘要
类风湿性关节炎(rheumatoid arthritis,RA)是一种慢性自身免疫性疾病,在世界范围内平均患病率约1%,我国患病率约4‰;其突出的临床表现为关节肿、痛、僵硬和畸形;目前尚无有效的治疗方法,现行治疗的目标主要是减轻症状,预防关节破坏及功能丧失,提高生活质量。RA发病机制未明,其主要病理特征为成纤维样滑膜细胞(fibroblast-like synoviocytes,FLS)过度增殖、炎性细胞浸润及新生血管形成等;增生的滑膜组织构成血管翳侵蚀关节软骨和骨,造成关节进行性破坏、畸形和功能丧失等。因此,滑膜增生对类风湿性滑膜炎的发展起着重要作用。近期研究表明,细胞增殖与细胞死亡关系密切,RA FLS增殖与死亡也许存在不平衡,进而导致滑膜增生。因此,抑制RA FLS增殖,诱导其凋亡进而降低滑膜增生可成为治疗RA有效策略之一。
弗氏完全佐剂(Freund's complete adjuvant,FCA)诱导的佐剂性关节炎(adjuvantarthritis,AA)是一种实验性关节炎模型,其关节病理改变及细胞和体液免疫与RA相似,可用作评价RA治疗的测试系统。
内抑素(endostatin)是一种强效内源性血管生成抑制因子,分子量为20kD左右,是胶原ⅩⅧ的降解产物,其抗血管生成活性机制可能是特异性抑制血管内皮细胞粘附、迁移和增殖,诱导其凋亡。近期研究证实,内抑素不仅可通过抑制内皮细胞功能(即抑制肿瘤新生血管形成),而且还可通过直接抑制肿瘤细胞迁移、增殖及诱导其凋亡而发挥抗肿瘤效应。FLS是RA病理改变的最终靶细胞,其增殖活跃,具有肿瘤转化细胞的特征,RA滑膜组织类似于局限性侵袭生长的肿瘤,提示治疗肿瘤性疾病的途径可用于治疗RA,包括凋亡诱导因子和抗血管生成因子。目前有关endostatin的研究主要集中于抗肿瘤活性与机制等,而对其它病理性血管形成如慢性炎症性血管生成的影响国内外报道很少;以FLS为靶点,探讨endostatin对RA的作用及机制国内外尚未见报道。我们前期研究表明,腹部皮下注射重组人内抑素(recombinant human endostatin,rhEndostatin;(1.25,2.5,5.0 mg·kg~(-1)·d~(-1),×7d)对大鼠AA有治疗作用,可明显减轻AA大鼠足爪肿胀程度,降低滑膜组织血管内皮(细胞)生长因子(vascular endothelial growth factor,VEGF)表达,减小滑膜微血管密度(microvessel density,MVD)。进一步研究证实,rhEndostatin(3.125,6.25,12.5,25,50μg/ml)可直接抑制AA FLS增殖并诱导其凋亡,但具体作用机制不清楚。本研究正是在此基础上进一步探讨rhEndostain对AA FLS作用的潜在机制,为RA治疗及寻找其治疗新靶点提供实验依据。
目的:①观察rhEndostatin对AA FLS细胞周期的影响;
②观察rhEndostatin对AA FLS细胞周期相关基因p53,p21,CDK_4,cyclinD_1,PCNAmRNA和CyclinD_1,PCNA蛋白表达的影响;
③观察rhEndostatin对AA FLS凋亡相关基因fas,bcl-2,c-fos,c-jun mRNA及c-Jun,NFκB,Caspase-3蛋白表达的影响;
④观察rhEndostatin对AA FLS胞质游离钙(ionized free calcium,Ca~(2+))的影响。探讨rhEndostatin抑制AA FLS增殖,促进其凋亡的分子及离子机制,为RA药物治疗及寻找其治疗新靶点提供实验依据。
方法:①AA大鼠模型制备:雄性SD大鼠,体质量140-160g,安徽医科大学实验动物中心提供,后足趾皮内注射FCA制备AA大鼠模型。
②滑膜组织准备:大鼠随机均分为正常组、AA模型组、rhEndostatin(2.5mg/kg)治疗组和甲氨蝶呤(methotrexate,MTX;(1mg/kg)治疗对照组;后三组造模后第10-16天,rhEndostatin治疗组大鼠腹部皮下注射rhEndostatin(2.5 mg·kg~(-1)·d~(-1)),MTX组大鼠腹部皮下注射MTX(1 mg/kg twice weekly),AA模型组及正常组大鼠给予等剂量的注射用水;第28天处死大鼠,取出滑膜层组织。
③FLS准备:应用正常和AA大鼠膝关节新鲜滑膜组织进行细胞培养,实验用传2代培养的滑膜细胞,通过流式细胞仪(flow cytometry,FCM)检测AA大鼠滑膜细胞血管细胞粘附分子-1(vascular cell adhesion molecule-1,VCAM-1)表达情况鉴定FLS。
④FLS细胞周期检测:传1代培养的正常和AA大鼠滑膜细胞接种于6孔培养板中,AA大鼠滑膜细胞分设AA模型组、rhEndostatin(50μg/ml)治疗组、MTX(1μg/ml)治疗组,用无血清的RPMI-1640培养液培养24h,使细胞周期同步化,继之换上含20%血清的RPMI-1640培养液,并相应加入rhEndostatin(终浓度50μg/ml)和MTX(终浓度1μg/ml),继续培养48h后收集细胞,FCM检测细胞周期。
⑤细胞周期相关基因检测:分别提取各组大鼠滑膜组织中RNA、蛋白质;实时荧光定量PCR法检测p53,p21,cyclinD_1,PCNA,CDK_4 mRNA表达;Western Blot法检测PCNA,CyclinD_1蛋白表达。
⑥凋亡相关基因检测:实时荧光定量PCR法检测各组大鼠滑膜组织中fas,bcl-2,c-fos,c-jun mRNA表达;Western Blot法检测c-Jun,NFκB,Caspase-3蛋白表达。
⑦AA FLS胞质Ca~(2+)检测:Fluo-3/AM作为Ca~(2+)指示剂,终浓度为50μg/ml rh-Endostatin灌流AA FLS,同时用激光共聚焦显微镜(confocal laser scanningmicroscope,CLSM)动态观察、记录AA FLS在有Ca~(2+)液和无Ca~(2+)液中胞质Ca~(2+)荧光强度(fluorescence intensity,FI)变化,检测rhEndostatin对AA FLS胞质Ca~(2+)浓度(cytosolic free calcium concentration,[Ca~(2+)]_i)的影响。
结果:①rhEndostatin对大鼠FLS细胞周期的影响:FCM检测和分析结果显示,正常组大鼠FLS细胞周期主要停留在G_0/G_1期,比例为68.3%,S期和G_2/M期细胞较少,分别为23.65%,6.32%;与正常组相比,AA模型组大鼠FLS G_1期比例明显减少,约为10.0%,大部分细胞进入S期,为65.6%,G_2/M期细胞比例接近19.5%;加入rhEndostatin(50μg/ml)后,G_1期细胞由AA模型组10.0%增至74.1%,而S期和G_2/M期细胞比例显著减少,分别为12.6%和4.15%。
②rhEndostatin对AA大鼠滑膜组织中细胞周期相关基因表达的影响:实时荧光定量PCR检测结果显示,rhEndostatin(2.5 mg/kg)能显著降低AA大鼠滑膜组织中p53,p21,cyclinD_1和PCNA mRNA表达水平(P＜0.01),增加CDK_4 mRNA表达(P＜0.01)。Western Blot检测证实,rhEndostatin治疗组大鼠滑膜组织中PCNA和CyclinD_1蛋白表达较AA模型组显著降低(P＜0.01)。
③rhEndostatin对AA大鼠滑膜组织中凋亡相关基因表达的影响:实时荧光定量PCR分析结果表明,rhEndostatin(2.5mg/kg)能明显提高AA大鼠滑膜组织中fas,bcl-2,c-fos和c-jun mRNA表达水平(P＜0.01)。Western Blot检测进一步证实,应用rhEndostatin治疗后,大鼠滑膜组织中43kD和48kD c-Jun蛋白和Caspase-3 p20表达水平较AA模型组显著提高(P＜0.01);但NFκB p65表达较AA模型组增加不明显(P＞0.05)。
④rhEndostatin对AA FLS[Ca~(2+)]_i的影响:CLSM检测结果显示,当细胞处于无Ca~(2+)液中时,rhEndostatin(50μg/ml)不能引起AA FLS胞质Ca~(2+) FI的改变。当细胞外缓冲液为有Ca~(2+)液时,终浓度为50μg/ml rhEndostatin灌流AA FLS可使胞质Ca~(2+)FI急剧增加达峰值,随即荧光开始减弱,FI随时间缓慢下降。
结论:①rhEndostatin抑制AA FLS增殖与其引起AA FLS细胞周期G_1期阻滞有关,其分子生物学基础可能是rhEndostatin抑制AA FLS CyclinD_1和PCNA的表达,并非依赖P53-P21-CDK-Cyclin经典途径。
②rhEndostatin促进AA FLS凋亡与其增加AA FLS fas,c-fos,c-jun,caspase-3基因表达与活化有关,该凋亡过程不依赖于bcl-2表达降低,也不能被bcl-2表达增加和NFkB活化所抑制。
③rhEndostatin可引起AA FLS胞外Ca~(2+)内流,钙稳态失衡是rhEndostatin诱发AAFLS损伤的一个早期的事件,细胞内钙超载可能作为AA FLS凋亡的一个重要始动环节。
Rheumatoid arthritis(RA) is a chronic autoimmune disease affecting approximately 1% and 0.4%of the population worldwide and nationwide,respectively.RA presents clinically with joint swelling,pain,stiffness,deformity and is not healed.The major goals of treatment of RA are to reduce pain and discomfort,to prevent joint destruction and loss of joint function,and to maintain a productive and active lifestyle.Up to date, the mechanisms that contribute to the pathogenesis of RA are unknown.The affected RA joint is characterized by pronounced synovial hyperplasia composed of extensive proliferation of fibroblast-like synoviocytes(FLS) and inflammatory cell infiltration with neovascularization.Pannus tissue comprising the hyperplastic synovium leads to progressive joint destruction,deformity and functional incapacitation,which is manifested as bone erosion and cartilage destruction.Thus,the synovial hyperplasia has a critical role in the propagation of rheumatoid synovitis.It is generally accepted that there is a close relationship between cell proliferation and cell death,and that there may be an imbalance between the proliferation and death of FLS in RA,which leads to synovial hyperplasia.For this reason,the interruption of proliferation and induction of apoptosis in RA FLS have been proposed as one of the promising strategies for treating RA by way of reducing synovial hyperplasia in situ.
Adjuvant arthritis(AA) is a model of experimental arthritis that is induced by injection of Freund's complete adjuvant(FCA).The similarities between the joint pathologies as well as the cellular and humoral immunities in AA and RA suggest that AA is a relevant animal model that acts as a useful test system for evaluating treatment of RA. Endostatin,a 20kD fragment of collagen XVIII,is a member of a group of powerfully endogenous antiangiogenic proteins that are activated by proteolytic processing.In fact, the antiangiogenic activity of endostatin is speculated to be specifically mediated by the inhibition of endothelial cell adhesion,migration and proliferation,and induction of apoptosis.Recently,endostatin has been studied not only for its inhibitory effects on vascular endothelial cell function but also its direct antitumor effects on cancer cell migration and proliferation,and induction of apoptosis.Fibroblast-like synoviocytes are the ultimate target cells of the pathologic changes in RA,also,they exhibit pre-neoplastic characteristic of transformed cells with active proliferation.The locally invasive tumourlike properties of RA synovial tissues suggest that approaches normally reserved for oncologic diseases might be useful in RA,including induction of apoptosis and antiangiogenesis agents.Studies on endostatin are mainly involved in its effects and mechanisms on anti-tumor now.There is few report on the effect of endostatin on upregulated angiogenesis in certain pathological conditions such as chronic inflammation. It is no reported that rhEndostatin has therapeutic effect on RA by targeting FLS. Previous studies have shown that subcutaneous administrations of recombinant human endostatin(rhEndostatin;(1.25,2.5,5.0 mg·kg~(-1)·d~(-1),×7d) to the abdomen have therapeutic effect on AA rats,which is characterized by significantly inhibition of paw swelling, reduction of microvessel density(MVD) and the expression of vascular endothelial growth factor(VEGF) in the synovium of AA rats.Also,rhEndostatin(3.125,6.25,12.5, 25,50μg/ml) can directly have influence on AA FLS such as inhibition of proliferation and induction of apoptosis.However,the mechanisms of effects of rhEndostatin on AA FLS in rats remain unclear.The aim of the current study was to understand the potential mechanisms,and to provide a experimental data for the development of new therapeutic interventions and targets of RA.
Objective:To clarify the molecular and ionic mechanisms of effect of rhEndostatin on AA FLS such as inhibition of proliferation and induction of apoptosis,and to provide a experimental data for the development of new therapeutic interventions and targets of RA,we investigated①the effect of rhEndostatin on cell cycle of AA FLS,②the effect of rhEndostatin on the expression of the cell cycle regulatory genes such as p53,p21, CDK4,cyclinD_1,PCNA mRNA and CyclinD_1,PCNA protein in AA FLS,③the effect of rhEndostatin on the expression of the apoptosis regulatory genes such as fas,bcl-2, c-fos,c-jun mRNA and c-Jun,NFr,B,Caspase-3 protein in AA FLS,and④the effect of rhEndostatin on the cytosolic ionized free calcium(Ca~(2+)) in AA FLS.
Methods:①Induction of the AA rat model:Male Sprague-Dawley(SD) rats weighing 140-160g were obtained from the Animal Center of Anhui Medical University.Rats were immunized on day 0 by intradermal injection of a 0.1-ml aliquot of FCA into the left hind paw.
②Preparation of synovial tissues:The rats were randomly divided into normal,AA control,rhEndostatin(2.5mg/kg)-treated and methotrexate(MTX;(1mg/kg)-treated groups,and immunized to induce AA rat model in the groups except normal one. Subcutaneous administrations of rhEndostatin(2.5mg·kg~(-1)·d~(-1)) and MTX(1mg/kg twice weekly) to the abdomen were started on day 10 post-immunization and continued until day 16 post-immunization.Normal and AA control group received the same volumes of phosphate-buffered saline(PBS).On day 28,the animals were sacrificed and the synovial tissues were promptly removed for subsequent experiments.
③Preparation of FLS:Synoviocytes were isolated from knee joints of the normal and AA rats,and cultured under permissive conditions.The synoviocytes were used in experiments from the second subculturing ones.The cells obtained from AA rats were identified by their expressed vascular cell adhesion molecule-1(VCAM-1) as evaluated by flow cytometry(FCM) analysis.
④Cell Cycle Analysis of FLS:The first subculturing synoviocytes obtained from normal and AA rats were plated in a 6-well plate.AA synoviocytes were divided into AA control,rhEndostatin(50μg/ml)-treated and MTX(1μg/ml)-treated groups.For synchronization,the cells were harvested in serum-free RPMI 1640 medium for 24h at 37℃.The cells were then placed in RPMI 1640 medium containing 20%(v/v) fetal calf serum(FCS).For rhEndostatin-treated and MTX-treated groups,the cells were treated with the designated doses of agents for 48 h at 37℃.The cells were collected and analysed by FCM.
⑤Detection of cell cycle regulatory genes:Total RNA and protein was extracted from each frozen synovial tissue sample obtained from rats in various groups.The expression of p53,p21,cyclinD_1,PCNA,CDK_4 mRNA was quantified by real-time fluorescent quantitative polymerase chain reaction(RT-FQ-PCR).The expression of PCNA, CyclinD_1 proteins was detected by westem blot analysis.
⑥Detection of apoptosis regulatory genes:The expression of fas,bcl-2,c-fos,c-jun mRNA in synovial tissue sample obtained from rats in various groups was quantified by RT-FQ-PCR.The expression of c-Jun,NFκB,Caspase-3 proteins was detected by westem blot analysis.
⑦Measurements of the cytosolic Ca~(2+) in AA FLS:The cultured AA FLS were loaded with the calcium ion-sensitive fluorescent indicator fluo-3/AM,and perfused with rhEndostatin at the concentration of 50μg/ml.At the same time a confocal laser scanning microscope(CLSM) was applied to measure changes of cytosolic Ca~(2+) fluorescence intensity(FI) in AA FLS when cells were immersed in the buffer with or without Ca~(2+),and to investigate the effect of rhEndostatin on cytosolic free calcium concentration([Ca~(2+)]_i) in AA FLS.
Results:①Effect of rhEndostatin on cell cycle of FLS:Flow cytometric analysis indicated that the cell cycle progression of FLS obtained from normal rats was arrested at G1 phase.The percentages of cells in G_0/G_1 phase,S phase,G_2/M phase were 68.3%, 23.65%,6.32%,respectively.The rate of AA FLS in G1 phase(10.0%) was significantly lower than that in normal control group.The cell cycle progression of AA FLS was mostly in S phase.The percentages of cells in S phase,G_2/M phase were 65.6%,19.5%, respectively.Recombinant human endostatin(50μg/ml) significantly increased G_1 phase cells as compared with those of AA FLS(74.1%versus 10.0%).The percentages of cells in S phase,G_2/M phase(12.6%,4.15%,) were significantly decreased compared with AA control group.
②Effect of rhEndostatin on the expression of the cell cycle regulatory genes in synovial tissues obtained from AA rats:Analysis by RT-FQ-PCR showed that rhEndostatin(2.5mg/kg) could significantly decrease the expression of p53,p21, cyclinD_1,PCNA mRNA and increase the expression of CDK_4 mRNA in synovial tissues obtained from AA rats(P＜0.01).Westem Blot analysis indicated that the expression of PCNA and CyclinD_1 protein in synovial tissues treated with rhEndostatin were significantly decreased than that in AA control group(P＜0.01).
③Effect of rhEndostatin on the expression of the apoptosis regulatory genes in synovial tissues obtained from AA rats:Real-time PCR analysis indicated that rhEndostatin(2.5mg/kg) could significantly increase the expression level of fas,bcl-2, c-fos and c-jun mRNA in synovial tissues obtained from AA rats(P＜0.01).The results of Western Blot analysis indicated that the expression of c-Jun protein(43kD,48kD) and Caspase-3 p20 in synovial tissues treated with rhEndostatin were significantly increased compared with that in AA control group(P＜0.01).But rhEndostatin could not significantly improve the expression of NFκB p65 in synovial tissues obtained from AA rats(P＞0.05).
④Effect of rhEndostatin on[Ca~(2+)]_i in AA FLS:Analysis by CLSM showed that rhEndostatin(50μg/ml) did not change cytosolic Ca~(2+) FI in AA FLS when cells were immersed in non-calcium extracelluar solution.When cells were immersed in the buffer with Ca~(2+) and perfused with rhEndostatin at the concentration of 50μg/ml,the cytosolic Ca~(2+) FI in AA FLS was rapidly increased to maximum and then gradually declined.
Conclution:①Suppression of CyclinD_1 and PCNA expression by rhEndostatin can produce a virtual inhibition of S-phase entry and arrest the cell cycle progression of AA FLS in G_1 phase,which induces inhibition of AA FLS proliferation and is not associated with the expression of P53,P21,CDK_4.
②Apoptosis induced by rhEndostatin in AA FLS is strongly associated with the increased expression and activation of fas,c-fos,c-jun,caspase-3,but not bcl-2,NFκB in AA FLS.
③Recombinant human endostatin can elicit the extracellular calcium influx in intact AA FLS.Imbalance of Ca~(2+) steady state induced by rhEndostatin is the very early events occur prior to AA FLS damage.Cytoplasmic Ca~(2+) overload may occur prior to any other molecular events of apoptosis in AA FLS.
弗氏完全佐剂(Freund's complete adjuvant,FCA)诱导的佐剂性关节炎(adjuvantarthritis,AA)是一种实验性关节炎模型,其关节病理改变及细胞和体液免疫与RA相似,可用作评价RA治疗的测试系统。
内抑素(endostatin)是一种强效内源性血管生成抑制因子,分子量为20kD左右,是胶原ⅩⅧ的降解产物,其抗血管生成活性机制可能是特异性抑制血管内皮细胞粘附、迁移和增殖,诱导其凋亡。近期研究证实,内抑素不仅可通过抑制内皮细胞功能(即抑制肿瘤新生血管形成),而且还可通过直接抑制肿瘤细胞迁移、增殖及诱导其凋亡而发挥抗肿瘤效应。FLS是RA病理改变的最终靶细胞,其增殖活跃,具有肿瘤转化细胞的特征,RA滑膜组织类似于局限性侵袭生长的肿瘤,提示治疗肿瘤性疾病的途径可用于治疗RA,包括凋亡诱导因子和抗血管生成因子。目前有关endostatin的研究主要集中于抗肿瘤活性与机制等,而对其它病理性血管形成如慢性炎症性血管生成的影响国内外报道很少;以FLS为靶点,探讨endostatin对RA的作用及机制国内外尚未见报道。我们前期研究表明,腹部皮下注射重组人内抑素(recombinant human endostatin,rhEndostatin;(1.25,2.5,5.0 mg·kg~(-1)·d~(-1),×7d)对大鼠AA有治疗作用,可明显减轻AA大鼠足爪肿胀程度,降低滑膜组织血管内皮(细胞)生长因子(vascular endothelial growth factor,VEGF)表达,减小滑膜微血管密度(microvessel density,MVD)。进一步研究证实,rhEndostatin(3.125,6.25,12.5,25,50μg/ml)可直接抑制AA FLS增殖并诱导其凋亡,但具体作用机制不清楚。本研究正是在此基础上进一步探讨rhEndostain对AA FLS作用的潜在机制,为RA治疗及寻找其治疗新靶点提供实验依据。
目的:①观察rhEndostatin对AA FLS细胞周期的影响;
②观察rhEndostatin对AA FLS细胞周期相关基因p53,p21,CDK_4,cyclinD_1,PCNAmRNA和CyclinD_1,PCNA蛋白表达的影响;
③观察rhEndostatin对AA FLS凋亡相关基因fas,bcl-2,c-fos,c-jun mRNA及c-Jun,NFκB,Caspase-3蛋白表达的影响;
④观察rhEndostatin对AA FLS胞质游离钙(ionized free calcium,Ca~(2+))的影响。探讨rhEndostatin抑制AA FLS增殖,促进其凋亡的分子及离子机制,为RA药物治疗及寻找其治疗新靶点提供实验依据。
方法:①AA大鼠模型制备:雄性SD大鼠,体质量140-160g,安徽医科大学实验动物中心提供,后足趾皮内注射FCA制备AA大鼠模型。
②滑膜组织准备:大鼠随机均分为正常组、AA模型组、rhEndostatin(2.5mg/kg)治疗组和甲氨蝶呤(methotrexate,MTX;(1mg/kg)治疗对照组;后三组造模后第10-16天,rhEndostatin治疗组大鼠腹部皮下注射rhEndostatin(2.5 mg·kg~(-1)·d~(-1)),MTX组大鼠腹部皮下注射MTX(1 mg/kg twice weekly),AA模型组及正常组大鼠给予等剂量的注射用水;第28天处死大鼠,取出滑膜层组织。
③FLS准备:应用正常和AA大鼠膝关节新鲜滑膜组织进行细胞培养,实验用传2代培养的滑膜细胞,通过流式细胞仪(flow cytometry,FCM)检测AA大鼠滑膜细胞血管细胞粘附分子-1(vascular cell adhesion molecule-1,VCAM-1)表达情况鉴定FLS。
④FLS细胞周期检测:传1代培养的正常和AA大鼠滑膜细胞接种于6孔培养板中,AA大鼠滑膜细胞分设AA模型组、rhEndostatin(50μg/ml)治疗组、MTX(1μg/ml)治疗组,用无血清的RPMI-1640培养液培养24h,使细胞周期同步化,继之换上含20%血清的RPMI-1640培养液,并相应加入rhEndostatin(终浓度50μg/ml)和MTX(终浓度1μg/ml),继续培养48h后收集细胞,FCM检测细胞周期。
⑤细胞周期相关基因检测:分别提取各组大鼠滑膜组织中RNA、蛋白质;实时荧光定量PCR法检测p53,p21,cyclinD_1,PCNA,CDK_4 mRNA表达;Western Blot法检测PCNA,CyclinD_1蛋白表达。
⑥凋亡相关基因检测:实时荧光定量PCR法检测各组大鼠滑膜组织中fas,bcl-2,c-fos,c-jun mRNA表达;Western Blot法检测c-Jun,NFκB,Caspase-3蛋白表达。
⑦AA FLS胞质Ca~(2+)检测:Fluo-3/AM作为Ca~(2+)指示剂,终浓度为50μg/ml rh-Endostatin灌流AA FLS,同时用激光共聚焦显微镜(confocal laser scanningmicroscope,CLSM)动态观察、记录AA FLS在有Ca~(2+)液和无Ca~(2+)液中胞质Ca~(2+)荧光强度(fluorescence intensity,FI)变化,检测rhEndostatin对AA FLS胞质Ca~(2+)浓度(cytosolic free calcium concentration,[Ca~(2+)]_i)的影响。
结果:①rhEndostatin对大鼠FLS细胞周期的影响:FCM检测和分析结果显示,正常组大鼠FLS细胞周期主要停留在G_0/G_1期,比例为68.3%,S期和G_2/M期细胞较少,分别为23.65%,6.32%;与正常组相比,AA模型组大鼠FLS G_1期比例明显减少,约为10.0%,大部分细胞进入S期,为65.6%,G_2/M期细胞比例接近19.5%;加入rhEndostatin(50μg/ml)后,G_1期细胞由AA模型组10.0%增至74.1%,而S期和G_2/M期细胞比例显著减少,分别为12.6%和4.15%。
②rhEndostatin对AA大鼠滑膜组织中细胞周期相关基因表达的影响:实时荧光定量PCR检测结果显示,rhEndostatin(2.5 mg/kg)能显著降低AA大鼠滑膜组织中p53,p21,cyclinD_1和PCNA mRNA表达水平(P＜0.01),增加CDK_4 mRNA表达(P＜0.01)。Western Blot检测证实,rhEndostatin治疗组大鼠滑膜组织中PCNA和CyclinD_1蛋白表达较AA模型组显著降低(P＜0.01)。
③rhEndostatin对AA大鼠滑膜组织中凋亡相关基因表达的影响:实时荧光定量PCR分析结果表明,rhEndostatin(2.5mg/kg)能明显提高AA大鼠滑膜组织中fas,bcl-2,c-fos和c-jun mRNA表达水平(P＜0.01)。Western Blot检测进一步证实,应用rhEndostatin治疗后,大鼠滑膜组织中43kD和48kD c-Jun蛋白和Caspase-3 p20表达水平较AA模型组显著提高(P＜0.01);但NFκB p65表达较AA模型组增加不明显(P＞0.05)。
④rhEndostatin对AA FLS[Ca~(2+)]_i的影响:CLSM检测结果显示,当细胞处于无Ca~(2+)液中时,rhEndostatin(50μg/ml)不能引起AA FLS胞质Ca~(2+) FI的改变。当细胞外缓冲液为有Ca~(2+)液时,终浓度为50μg/ml rhEndostatin灌流AA FLS可使胞质Ca~(2+)FI急剧增加达峰值,随即荧光开始减弱,FI随时间缓慢下降。
结论:①rhEndostatin抑制AA FLS增殖与其引起AA FLS细胞周期G_1期阻滞有关,其分子生物学基础可能是rhEndostatin抑制AA FLS CyclinD_1和PCNA的表达,并非依赖P53-P21-CDK-Cyclin经典途径。
②rhEndostatin促进AA FLS凋亡与其增加AA FLS fas,c-fos,c-jun,caspase-3基因表达与活化有关,该凋亡过程不依赖于bcl-2表达降低,也不能被bcl-2表达增加和NFkB活化所抑制。
③rhEndostatin可引起AA FLS胞外Ca~(2+)内流,钙稳态失衡是rhEndostatin诱发AAFLS损伤的一个早期的事件,细胞内钙超载可能作为AA FLS凋亡的一个重要始动环节。
Rheumatoid arthritis(RA) is a chronic autoimmune disease affecting approximately 1% and 0.4%of the population worldwide and nationwide,respectively.RA presents clinically with joint swelling,pain,stiffness,deformity and is not healed.The major goals of treatment of RA are to reduce pain and discomfort,to prevent joint destruction and loss of joint function,and to maintain a productive and active lifestyle.Up to date, the mechanisms that contribute to the pathogenesis of RA are unknown.The affected RA joint is characterized by pronounced synovial hyperplasia composed of extensive proliferation of fibroblast-like synoviocytes(FLS) and inflammatory cell infiltration with neovascularization.Pannus tissue comprising the hyperplastic synovium leads to progressive joint destruction,deformity and functional incapacitation,which is manifested as bone erosion and cartilage destruction.Thus,the synovial hyperplasia has a critical role in the propagation of rheumatoid synovitis.It is generally accepted that there is a close relationship between cell proliferation and cell death,and that there may be an imbalance between the proliferation and death of FLS in RA,which leads to synovial hyperplasia.For this reason,the interruption of proliferation and induction of apoptosis in RA FLS have been proposed as one of the promising strategies for treating RA by way of reducing synovial hyperplasia in situ.
Adjuvant arthritis(AA) is a model of experimental arthritis that is induced by injection of Freund's complete adjuvant(FCA).The similarities between the joint pathologies as well as the cellular and humoral immunities in AA and RA suggest that AA is a relevant animal model that acts as a useful test system for evaluating treatment of RA. Endostatin,a 20kD fragment of collagen XVIII,is a member of a group of powerfully endogenous antiangiogenic proteins that are activated by proteolytic processing.In fact, the antiangiogenic activity of endostatin is speculated to be specifically mediated by the inhibition of endothelial cell adhesion,migration and proliferation,and induction of apoptosis.Recently,endostatin has been studied not only for its inhibitory effects on vascular endothelial cell function but also its direct antitumor effects on cancer cell migration and proliferation,and induction of apoptosis.Fibroblast-like synoviocytes are the ultimate target cells of the pathologic changes in RA,also,they exhibit pre-neoplastic characteristic of transformed cells with active proliferation.The locally invasive tumourlike properties of RA synovial tissues suggest that approaches normally reserved for oncologic diseases might be useful in RA,including induction of apoptosis and antiangiogenesis agents.Studies on endostatin are mainly involved in its effects and mechanisms on anti-tumor now.There is few report on the effect of endostatin on upregulated angiogenesis in certain pathological conditions such as chronic inflammation. It is no reported that rhEndostatin has therapeutic effect on RA by targeting FLS. Previous studies have shown that subcutaneous administrations of recombinant human endostatin(rhEndostatin;(1.25,2.5,5.0 mg·kg~(-1)·d~(-1),×7d) to the abdomen have therapeutic effect on AA rats,which is characterized by significantly inhibition of paw swelling, reduction of microvessel density(MVD) and the expression of vascular endothelial growth factor(VEGF) in the synovium of AA rats.Also,rhEndostatin(3.125,6.25,12.5, 25,50μg/ml) can directly have influence on AA FLS such as inhibition of proliferation and induction of apoptosis.However,the mechanisms of effects of rhEndostatin on AA FLS in rats remain unclear.The aim of the current study was to understand the potential mechanisms,and to provide a experimental data for the development of new therapeutic interventions and targets of RA.
Objective:To clarify the molecular and ionic mechanisms of effect of rhEndostatin on AA FLS such as inhibition of proliferation and induction of apoptosis,and to provide a experimental data for the development of new therapeutic interventions and targets of RA,we investigated①the effect of rhEndostatin on cell cycle of AA FLS,②the effect of rhEndostatin on the expression of the cell cycle regulatory genes such as p53,p21, CDK4,cyclinD_1,PCNA mRNA and CyclinD_1,PCNA protein in AA FLS,③the effect of rhEndostatin on the expression of the apoptosis regulatory genes such as fas,bcl-2, c-fos,c-jun mRNA and c-Jun,NFr,B,Caspase-3 protein in AA FLS,and④the effect of rhEndostatin on the cytosolic ionized free calcium(Ca~(2+)) in AA FLS.
Methods:①Induction of the AA rat model:Male Sprague-Dawley(SD) rats weighing 140-160g were obtained from the Animal Center of Anhui Medical University.Rats were immunized on day 0 by intradermal injection of a 0.1-ml aliquot of FCA into the left hind paw.
②Preparation of synovial tissues:The rats were randomly divided into normal,AA control,rhEndostatin(2.5mg/kg)-treated and methotrexate(MTX;(1mg/kg)-treated groups,and immunized to induce AA rat model in the groups except normal one. Subcutaneous administrations of rhEndostatin(2.5mg·kg~(-1)·d~(-1)) and MTX(1mg/kg twice weekly) to the abdomen were started on day 10 post-immunization and continued until day 16 post-immunization.Normal and AA control group received the same volumes of phosphate-buffered saline(PBS).On day 28,the animals were sacrificed and the synovial tissues were promptly removed for subsequent experiments.
③Preparation of FLS:Synoviocytes were isolated from knee joints of the normal and AA rats,and cultured under permissive conditions.The synoviocytes were used in experiments from the second subculturing ones.The cells obtained from AA rats were identified by their expressed vascular cell adhesion molecule-1(VCAM-1) as evaluated by flow cytometry(FCM) analysis.
④Cell Cycle Analysis of FLS:The first subculturing synoviocytes obtained from normal and AA rats were plated in a 6-well plate.AA synoviocytes were divided into AA control,rhEndostatin(50μg/ml)-treated and MTX(1μg/ml)-treated groups.For synchronization,the cells were harvested in serum-free RPMI 1640 medium for 24h at 37℃.The cells were then placed in RPMI 1640 medium containing 20%(v/v) fetal calf serum(FCS).For rhEndostatin-treated and MTX-treated groups,the cells were treated with the designated doses of agents for 48 h at 37℃.The cells were collected and analysed by FCM.
⑤Detection of cell cycle regulatory genes:Total RNA and protein was extracted from each frozen synovial tissue sample obtained from rats in various groups.The expression of p53,p21,cyclinD_1,PCNA,CDK_4 mRNA was quantified by real-time fluorescent quantitative polymerase chain reaction(RT-FQ-PCR).The expression of PCNA, CyclinD_1 proteins was detected by westem blot analysis.
⑥Detection of apoptosis regulatory genes:The expression of fas,bcl-2,c-fos,c-jun mRNA in synovial tissue sample obtained from rats in various groups was quantified by RT-FQ-PCR.The expression of c-Jun,NFκB,Caspase-3 proteins was detected by westem blot analysis.
⑦Measurements of the cytosolic Ca~(2+) in AA FLS:The cultured AA FLS were loaded with the calcium ion-sensitive fluorescent indicator fluo-3/AM,and perfused with rhEndostatin at the concentration of 50μg/ml.At the same time a confocal laser scanning microscope(CLSM) was applied to measure changes of cytosolic Ca~(2+) fluorescence intensity(FI) in AA FLS when cells were immersed in the buffer with or without Ca~(2+),and to investigate the effect of rhEndostatin on cytosolic free calcium concentration([Ca~(2+)]_i) in AA FLS.
Results:①Effect of rhEndostatin on cell cycle of FLS:Flow cytometric analysis indicated that the cell cycle progression of FLS obtained from normal rats was arrested at G1 phase.The percentages of cells in G_0/G_1 phase,S phase,G_2/M phase were 68.3%, 23.65%,6.32%,respectively.The rate of AA FLS in G1 phase(10.0%) was significantly lower than that in normal control group.The cell cycle progression of AA FLS was mostly in S phase.The percentages of cells in S phase,G_2/M phase were 65.6%,19.5%, respectively.Recombinant human endostatin(50μg/ml) significantly increased G_1 phase cells as compared with those of AA FLS(74.1%versus 10.0%).The percentages of cells in S phase,G_2/M phase(12.6%,4.15%,) were significantly decreased compared with AA control group.
②Effect of rhEndostatin on the expression of the cell cycle regulatory genes in synovial tissues obtained from AA rats:Analysis by RT-FQ-PCR showed that rhEndostatin(2.5mg/kg) could significantly decrease the expression of p53,p21, cyclinD_1,PCNA mRNA and increase the expression of CDK_4 mRNA in synovial tissues obtained from AA rats(P＜0.01).Westem Blot analysis indicated that the expression of PCNA and CyclinD_1 protein in synovial tissues treated with rhEndostatin were significantly decreased than that in AA control group(P＜0.01).
③Effect of rhEndostatin on the expression of the apoptosis regulatory genes in synovial tissues obtained from AA rats:Real-time PCR analysis indicated that rhEndostatin(2.5mg/kg) could significantly increase the expression level of fas,bcl-2, c-fos and c-jun mRNA in synovial tissues obtained from AA rats(P＜0.01).The results of Western Blot analysis indicated that the expression of c-Jun protein(43kD,48kD) and Caspase-3 p20 in synovial tissues treated with rhEndostatin were significantly increased compared with that in AA control group(P＜0.01).But rhEndostatin could not significantly improve the expression of NFκB p65 in synovial tissues obtained from AA rats(P＞0.05).
④Effect of rhEndostatin on[Ca~(2+)]_i in AA FLS:Analysis by CLSM showed that rhEndostatin(50μg/ml) did not change cytosolic Ca~(2+) FI in AA FLS when cells were immersed in non-calcium extracelluar solution.When cells were immersed in the buffer with Ca~(2+) and perfused with rhEndostatin at the concentration of 50μg/ml,the cytosolic Ca~(2+) FI in AA FLS was rapidly increased to maximum and then gradually declined.
Conclution:①Suppression of CyclinD_1 and PCNA expression by rhEndostatin can produce a virtual inhibition of S-phase entry and arrest the cell cycle progression of AA FLS in G_1 phase,which induces inhibition of AA FLS proliferation and is not associated with the expression of P53,P21,CDK_4.
②Apoptosis induced by rhEndostatin in AA FLS is strongly associated with the increased expression and activation of fas,c-fos,c-jun,caspase-3,but not bcl-2,NFκB in AA FLS.
③Recombinant human endostatin can elicit the extracellular calcium influx in intact AA FLS.Imbalance of Ca~(2+) steady state induced by rhEndostatin is the very early events occur prior to AA FLS damage.Cytoplasmic Ca~(2+) overload may occur prior to any other molecular events of apoptosis in AA FLS.
引文
1 吴丽,魏伟.类风湿关节炎中血管生成的分子机制.中国药理学通报,2004,20(10):1098-10102.
2 Firestein GS.Invasive fibroblast-like synoviocytes in rheumatoid arthritis:passive responders or transformed aggressors.Arthritis Rheum,1996,39(11):1781-1790.
3 Nishioka K,Hasunuma T,Kato T,et al.Apoptosis in rheumatoid arthritis:a novel pathway in the regulation of synovial tissue.Arthritis Rheum,1998,41(1):1-9.
4 Paleolog EM.Angiogenesis in rheumatoid arthritis.Arthritis Res,2002,4(suppl 3):S81-S90.
5 Paleolog EM,Miotla JM.Rheumatoid arthritis:A target for antiangiogenic therapy.Humana Press Inc,2001,8(6):129-149.
6 O'Reilly MS,Boehm T,Shing Y,et al.Endostatin:an endogenous inhibitor of angiogenesis and tumor growth.Cell,1997,88(2):227-285.
7 Dhanabal M,Ramchandran R,Waterman MJ,et al.Endostatin induces endothelial cell apoptosis.J Biol Chem,1999,274(17):11721-11726.
8 Cui R,Ohashi R,Takahashi F,et al.Signal transduction mediated by endostatin directly modulates cellular function of lung cancer cells in vitro.Cancer Sci,2007,98(6):830-837.
9 Wilson RF,Morse MA,Pei P,et al.Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells.Anticancer Res,2003,23(2B):1289-1295.
10 Hui A,Kulkami GV,Hunter WL,et al.Paclitaxel selectively induces mitotic arrest and apoptosis in proliferating bovine synoviocytes.Arthritis Rheum,1997,40(6):1073-1084.
11 Firestein GS.Evolving concepts of rheumatoid arthritis.Nature,2003,423(6937):356-361.
12 夏丽娟,陈飞虎,黄学应,等.重组人内抑素对佐剂性关节炎大鼠滑膜组织血管内皮细胞生长因子表达的影响.中国临床药理学与治疗学,2006,11(7):760-763.
13 夏丽娟,陈飞虎,任斌,等.重组人内抑素对佐剂性关节炎大鼠滑膜细胞增殖及产生细胞因子的影响.中国药理学通报,2007,23(1):59-63.
14 Huang XY,Chen FH,Li J,et al.Mechanism of fibroblast-like synoviocyte apoptosis induced by recombinant human endostatin in rats with adjuvant arthritis.Anat Rec,2008,May 28[Epub ahead of print].
15 李伟,张远强,刘新平,等.佐剂型类风湿关节炎模型改良与DDR2表达的研究.中国组织化学与细胞化学杂志,2003,12(1):89-93.
16 刘琼,王晨璐,方剑乔.类风湿性关节炎动物模型的研究进展.医学综述,2006,12(5):313-316.
17 陈柏松,徐玉东,钟淑琦,等.大鼠佐剂性关节炎模型的建立与评价.哈尔滨医科大学学报,2005,39(6):489-491.
18 Kim KM,Lee K,Hong YS,et al.Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cells.Exp Mol Med,2000,32(4):246-254.
19 Wang X.The expanding role of mitochondria in apoptosis.Genes Dev,2001,15(22):2922-2933.
20 Desagher S,Martinou JC.Mitochondria as the central control point of apoptosis.Trends Cell Biol,2000,10(9):369-377.
21 Ashkenazi A,Dixit VM.Death receptors:signaling and modulation.Science,1998,281(5381):1305-1308.
22 Sun XM,MacFarlane M,Zhuang J,et al.Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis.J Biol Chem,1999,274(8):5053-5060.
23 Nakamura K,Bossy-Wetzel E,Bums K,et al.Changes in endoplasmic reticulum luminal environment affect cell sensitivity to apoptosis.J Cell Biol,2000,150(4):731-740.
24 Thompson CB.Apoptosis in the pathogenesis and treatment of disease.Science,1995,267(5203):1456-1462.
25 Cutolo M,Sulli A,Barone A,et al.Sex hormones,proto-oncogene expression and apoptosis:their effects on rheumatoid synovial tissue.Clin Exp Rheumatol,1996,14(1):87-94.
26 Matsumoto S,Muller-Ladner U,Gay RE,et al.Ultrastructural demonstration of apoptosis,Fas and Bcl-2 expression of rheumatoid synovial fibroblasts.J Rheumatol,1996,23(8):1345-1352.
27 Nishioka K,Hasunuma T,Kato T,et al.Apoptosis in rheumatoid arthritis:a novel pathway in the regulation of synovial tissue.Arthritis Rheum,1998,41(1):1-9.
28 Pope RM.Apoptosis as a therapeutic tool in rheumatoid arthritis.Nat Rev Immunol,2002,2(7):527-535.
29 Firestein GS.Invasive fibroblast-like synoviocytes in rheumatoid arthritis:passive responders or transformed aggressors.Arthritis Rheum,1996,39(11):1781-1790.
30 刘继红,李卫东,林志彬.类风湿性关节炎细胞凋亡的研究现状.中国临床药理学和治疗学,2003,8(2):232-236.
31 Halestrap AP,Clarke SJ,Javadov SA.Mitochondria permeability transition pore opening during myocardial reperfusion—a target for cardioprotection.Cardiovasc Res,2004,61(3):372-385.
32 Murphy AN,Bredesen DE,Cortopassi G,et al.Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria.Proc Natl Accad Sci USA,1996,93(18):9893-9898.
33 Ichimiya M,Chang SH,Liu H,et al.Effect of Bcl-2 on oxidant-induced cell death and intracellular Ca~(2+) mobilization.Am J Physiol,1998,275(3 Pt 1):C832-C839.
34 Zhu L,Ling S,Yu XD,et al.Modulation of mitochondrial Ca~(2+) homeostasis by Bcl-2.J Biol Chem,1999,274(47):33267-33273.
35 Yang J,Liu X,Bhalla K,et al.Prevention of apoptosis by Bcl-2:release of cytochrome C from mitochondria blocked.Science,1997,275(5303):1129-1132.
36 Liu H,Pope RM.The role of apoptosis in rheumatoid arthritis.Curr Opin Pharmacol,2003,3(3):317-322.
37 Perlman H,Georganas C,Pagliari LJ,et al.Bcl-2 expression in synovial fibroblasts is essential for maintaining mitochondrial homeostasis and cell viability.J Immunol,2000,164(10):5227-5235.
38 Chen R,Valencia I,Zhong F,et al.Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1,4,5-trisphosphate.J Cell Biol,2004,166(2):193-203.
39 张兴民,蒋明,郑德先,等.类风湿关节炎病人滑膜细胞增生与fas和bcl-2基因的表达.中华医学杂志,1998,78(3):175-178.
40 Sionov RV,Haupt Y.Apoptosis by p53:mechanisms,regulation,and clinical implications.Springer Semin Immunopathol,1998,19(3):345-362.
41 Tak PP,Zvaifler NJ,Green DR,et al.Rheumatoid arthritis and p53:how oxidative stress might Alter the course of inflammation diseases.Immunol Today,2000,21(2):78-82.
42 Tak PP,Klapwijk MS,Broersen SFM,et al.Apoptosis and p53 expression in rat adjuvant arthritis.Arthritis Res,2000,2(3):229-235.
43 Yamanishi Y,Boyle DL,Pinkoski MJ,et al.Regulation of joint destruction and inflammation by p53 in collagen-induced-arthritis.Am J Pathol,2002,160(1):123-130.
44 Yue L,Shen YX,Feng LJ,et al.Blockage of the formation of new blood vessels by recombinant human endostatin contributes to the regression of rat adjuvant arthritis.Eur J Pharmacol,2007,567:166-170.
45 Krammer PH.CD95's deadly mission in the immune system.Nature,2000,407(6805):789-795.
46 Itoh K,Hase H,Kojima H,et al.Central role of mitochondria and p53 in Fas- mediated apoptosis of rheumatoid synovial fibroblasts.Rheumatology,2004,43(3):277-285.
47 Chou CT,Yang JS,Lee MR.Apoptosis in rheumatoid arthritis—expression of Fas,Fas-L,p53,and Bcl-2 in rheumatoid synovial tissues.J Pathol,2001,193(1):110-116.
48 Lech K,Andeson K,Brent K.DNA-bound fos proteins activate transcription in yeast.Cell,1988,52(2):179-184.
49 Smeyne RJ,Vendrell MV,Hayward M,et al.Continuous c-fos expression precedes programmed cell death in vivo.Nature,1993,363(13):166-169
50 Wagstaff SC,Bowler WB,Gallagher JA,et al.Extracellular ATP activates multiple signaling pathways and potentiates growth factor-induced c-fos gene expression in MCF-7 breast cancer cells.Carcinogenesis,2000,21(12):2175-2181.
51 林华,魏海燕,蒋青,等.原发性骨质疏松骨组织c-fos,c-jun和p53基因的表达.中国骨肿瘤骨病,2003,2(6):368-371.
52 Leppa S,Bohmann D.Diverse functions of JNK signaling and c-Jun in stress response and apoptosis.Oncogene,1999,18(45):6158-6162.
53 Shaulian E,Karin M.AP-1 as a regulator of cell life and death.Nat Cell Biol,2002,4(5):E131-136.
54 Bossy-Wetzel E,Bakiri L,Yaniv M.Induction of apoptosis by the transcription factor c-Jun.Embo J,1997,16(7):1695-1709.
55 Kolbus A,Herr I,Schreiber M,et al.c-Jun-dependent CD95-L expression is a ratelimiting step in the induction of apoptosis by alkylating agents.Mol Cell Biol,2000,20(2):575-582.
56 Cheung NS,Carroll FY,Larm JA,et al.Kainat-induced apoptosis,correlates with c-jun activation in cultured cerebellar granile cells.J Neutosci Res,1998,52(1):69-82
57 Baldwin AS.The NF-κB,IκB proteins new discoveries and insights.Annu Rev Immunol,1996,14(2):649-683.
58 黄培林,朱世能,陆世伦.NFκB,IκB与肿瘤细胞凋亡.实用癌症杂志,2001,16(1):103-104.
59 Han Z,Boyle DL,Manning AM,et al.AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis.Autoimmunity,1998,28(4):197-208.
60 Sioud M,Mellbye O,Forre O.Analysis of the NF-κB p65 subunit,Fas antigen,Fas ligand and Bcl-2-related proteins in the synovium of RA and polyarticular JRA.Clin Exp Rheumatol,1998,16(2):125-134.
61 Chen F,Castranova V,Shi X,et al.New insights into the role of nuclear factorkappaB,a ubiquitous transcription factor in the initiation of diseases.Clin Chem,1999,45(1):7-17.
62 Campbell IK,Gerondakis S,O'Donnell K,et al.Distinct roles for the NF-kappaB1(p50) and c-Rel transcription factors in inflammatory arthritis.J Clin Invest,2000105(12):1799-1806.
63 韩飞,尤欣,唐福林.核因子κB在类风湿关节炎滑膜组织中的表达及意义.中华风湿病学杂志,2004,8(3):143-146.
64 Handel ML,Mcmorrow LB,Gravallese EM.NF-kappa B in rheumatoid synovium:location of p50 and p65.Arthritis Rheum,1995,38(12):1762-1770.
65 PoterAG,Janieke RU.Emerging roles of caspase-3 in apoptosis.Cell Death Differ,1999,6(2):99-104.
66 Saikumar P,Dong Z,Mikhailov V,et al.Apoptosis:definition,mechanism,and relevance to disease.Am J Med,1999,107(5):489-506.
67 Hengartner MO.The biochemistry of apoptosis.Nature,2000,407(6805):770-776
68 Cohen GM.Caspases:the executioners of apoptosis.Biochem J,1997,326(1):1-16.
69 Yeh JY,Hsu SC,Han SH,et al.Mitogen-activated protein kinase kinase antagonized fas-associated Death Domain Protein-mediated apoptosis by induced FLICE-inhibitory protein expression.J Exp Med,1998,188(10):1795-1802.
70 刘景生主编.细胞信息与调控(第二版).北京:中国协和医科大学出版社.2004
71 唐海林,苏琦.钙离子信号与细胞凋亡关系的研究进展.南华大学学报(医学版),2006,34(5):663-666.
72 曾娅莉,黄文芳,卢贤瑜.细胞凋亡时线粒体钙离子信号调节因素研究进展.国际检验医学杂志,2006,27(6):543-545
73 Cho MR,Marler JP,Thatte HS,et al.Contorl if calcium entry in human fiborblasts by ferquency-dependent electrical stimulation.Front Biosci,2002,7(1):1-8.
74 史绢,李继硕.细胞内钙成像和钙测定的基本原理及应用.神经解剖学杂志,2006,22(4):455-462.
75 孙玮,路菊,潘峰,等.牛磺酸对乳鼠心肌细胞内钙浓度的影响.氨基酸和生物资源,2007,29(3):60-62.
76 李谨,蒋春梅,徐艳,等.硝苯地平对人牙龈成纤维细胞内Ca~(2+)含量影响的激光共聚焦显微观察.口腔医学研究,2006,22(5):495-497.
77 Sun Y,Vernier PT,Behrend M,et al.Fluorescence microscopy imaging of electroperturbation in mammalian cells.J Biomed Opt,2006,11(2):124-127.
78 孙文武,胡芬,杨文修.热和低渗刺激活化胞外Ca~(2+)内流机制升高大鼠滑膜细胞[Ca~(2+)]i.科学通报,2007,52(23):2752-2758.
79 Parekh AB,Reinhold P.Store depletion and calcium influx.Physiol Rev,1997,77(4):901-930
80 郭静,蒲咏梅,张东才.钙离子信号与细胞凋亡.生物物理学报,2005,21(1):1-18.
81 Bernardi P.Mitochondrial transport of cations:channels,exchangers,and permeability transition.Physiol Rev,1999,79(4):1127-1155.
82 Missiaen L,Robberecht W,Van Den Bosch L et al.Abnormal intracellular Ca~(2+)homeostasis and disease.Cell Calcium,2000;28(1):1-21.
83 Van den Heuvel,S.Cell-cycle regulation.Worm Book,2005,Sep21:1-16.
84 Branzei D,Foiani M.Regulation of DNA repair throughout the cell cycle.Nat Rev Mol Cell Biol,2008,9(4):297-308.
85 Yang K,Hitomi M,Stacey DW.Variations in cyclin D_1 levels through the cell cycle determine the proliferative fate of a cell.Cell Div,2006,1:32.
86 刘巧红,沈凌汛,滕云.类风湿关节炎滑膜细胞的增殖及细胞周期的研究.临床内科杂志,2004,21(12):814-816.
87 Xu R,Du P,Fan JJ,et al.High-level exepression and secretion of recombinant mouse endostatin by Escherichia coil.Protein Expr Purif,2002,24(3):453-459.
88 Liu G.;Lozano G.p21 Stability:linking chaperones to cell cycle checkpoint.Cancer Cell,2005,7(2):113-114.
89 He G,Siddik ZH,Huang Z,et al.Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities.Oncogene,2005,24(18):2929-2943.
90 Seville LL,Shah N,Westwell AD,et al.Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer.Curr Cancer Drug Targets,2005,5(3):159-170
91 Barboule N,Mazars P,Baldin V,et al.Expression of p21 WAF_1/CIP_1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma.Int J Cancer,1995,63(5):611-615.
92 Baretton GB,Klenk U,Dieold J,et al.Proliferation and apoptosis associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy:prognostic significance of p21 WAF_1/CIP_1 expression.Br J Cancer,1999,80(3-4):546-555.
93 周美英,谢立香.子宫内膜癌P21CIP1/WAF1和PCNA表达的研究.中国妇幼保健,2007,22(14):1991-1993.
94 朱江军,叶招明.骨肉瘤G1细胞周期调控因子研究进展.国际骨科学杂志,2006,27(6):344-347.
95 Hanai J,Dhanabal M,Karumanchi SA,et al.Endostatin causes G1 arrest of endothelial cells through inhibition of cyclinD_1.J Biol Chem,2002,277(19):16464- 16469.
96 Sakayama K,Fujibuchi T,Kidani T,et al.proliferative activity of osteosarcoma cells:comparison of osteoblastic and nonosteoblastic regions.J Orthop Sci,2003,8(5):678-682.
97 宋楠萌,桑建利,徐恒.增殖细胞核抗原(PCNA)的分子结构及其生物学功能研究进展.自然科学进展,2006,16(10):1201-1209.
1 吴丽,魏伟.类风湿关节炎中血管生成的分子机制.中国药理学通报,2004,20(10):1098-10102.
2 Paleolog EM,Miotla JM.Rheumatoid arthritis:A target for antiangiogenic therapy.Humana Press Inc,2001,8(6):129-149.
3 Wollhim FA.New function for COX-2 in health and disease.Arthritis Research,1999,1(1):45-49.
4 董怡,赵岩.抗风湿新药的概述.中国新药杂志,2001,10(1):10-14.
5 刘雁,李志军.非甾体抗炎药物的药理及临床应用进展.中国医院药学杂志,2000,20(12):748-750.
6 刘扬渝,董碧蓉.类风湿性关节炎药物治疗及策略进展.现代临床医学,2006,32(1):74-76.
7 Vane JR.Towards a better aspirin.Nature,1994,367(6460):215-216.
8 Vane JR,Botting RM.Mechanism of action of anti-inflammatory drugs.Scand J Rheumatol,1996,102(Suppl):9-21.
9 Cannon G,Caldwell J,Holt P,et al.MK-0966,a specific COX-2 inhibitor,has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis in a 26 week controlled clinical trial.Arthritis Rheum,1998,41(Suppl 9):196.
10 Geis GS,Stead H,Morant S,et al.Efficacy and safety of celecoxib,a specific COX-2 inhibitor,in patients with rheumatioid arthritis.Arthritis Rheum,1998,41(Suppl 9):316.
11 刘肖平.特异性COX-2抑制剂临床应用安全性新动态.实用疼痛学杂志,2005,1(2):66-68.
12 Scott DL.Advances in the medical management of rheumatoid arthritis.Hosp Med,2002,63(5):294-297.
13 邱一华,骆合德.类风湿性关节炎的药物治疗进展.中国综合临床,2001,17(7): 485-487.
14 Conn DL,Lim SS.New role for an old friend:prednisone is a disease-modifying agent in early rheumatoid arthritis.Curr Opin Rheumatol,2003,15(3):193-196.
15 曾应馀,刘建平.类风湿关节炎的药物治疗进展.中华内科杂志,1997,36(4):273-275.
16 Tsakonas E,Fitzgerald AA,Fitzcharles MA,et a.l Conse-quences of delayed therapy with second-line agents in rheumatoid arthritis:a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis study.J Rheumatol,2000,27(3):623-629.
17 Lard LR,Visser H,Speyer I,et al.Early versus delayed treatment in patients with recent-onset rheumatoid arthritis:comparison of two cohorts who received different treatment strategies[J].Am J Med,2001,111(6):446-451
18 Kremer JM.Methotrexate and emerging therapies.Rheum Dis Clin North Am,1998,24(3):651-658
19 Aringer M,Graninger WB.Treating rheumatoid arthritis with new disease modifying drugs[J].Acta Med Austriaca,2002,29(1):33-35.
20 Yocum DE,Solinger AM,Tesser J,et al.Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis:results of a phase Ⅰ,single dose,dose escalating trial.J Rheumatol,1998,25(7):1257-1262.
21 Vandenbark AA,Morgan E,Bartholomew R,et al.TCR peptide therapy in human autoimmune diseases[J].Neurochem Res,2001,26(6):713-730.
22 Moreland LW,Morgan EE,Adamson TC,et al.T cell receptor peptide vaccination in rheumatoid arthritis:a placebo-controlled trial using a combination of Vbeta_3,Vbeta_(14),and Vbeta_(17) peptides.Arthritis Rheum.1998,41(11):1919-1929.
23 张新梅,赵文明.类风湿性关节炎免疫治疗的研究进展.医学综述,2004,10(2):115-117.
24 王韫秀,王洪涛,刘亭威.类风湿性关节炎药物治疗新进展.实用药物与临床,2006,(6)4:253-254.
25 Walsh NC,Gravallese EM.Bone loss in inflammatory arthritis:mechanisms and treatment strategies.Curr Opin Rheumatol,2004,16(4):419-427.
26 Tak PP,Bresnihan B.The pathogenesis and prevention of joint damage in rheumatoid arthritis:advances from synovial biopsy and tissue analysis.Arthritis Rheum,2000,43(12):2619-2633.
27 Vervoordeldonk MJ,Tak PP.Cytokines in rheumatoid arthritis.Curr Rheumatol Rep,2002,4(3):208-217.
28 Tak PP,Smeets TJ,Daha MR,et al.Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity.Arthritis Rheum,1997,40(2):217-225.
29 Olsen NJ,Stein CM.New drugs for rheumatoid arthritis.N Engl J Med,2004,350(21):2167-2179.
30 刘彧,韩星海,孟济明.生物制剂在类风湿关节炎治疗中的应用.中华风湿病学杂志,2003,7(5):300-302.
31 Adriaansen J,Vervoordeldonk MJ,Tak PP.Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis:innovative vectors and therapeutic genes.Rheumatology(Oxford),2006,45(6):656-668.
32 牛丽娟,张立生.类风湿性关节炎药物治疗的进展.实用疼痛学杂志,2006,2(2):106-110.
33 Flendrie M,Creemers MC,Welsing PM,et al.The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis;a longitudinal observational study.Rheumatology (Oxford),2005,44(4):472-478.
34 Hamilton K,Clair EW.Tumour necrosis factor-alpha blockade:a new era for effective management of rheumatoid arthritis.Expert Opin Pharmacother,2000, 1(5):1041-1052.
35 Cohen SB,Moreland LW,Cush JJ,et al.A multicentre,double blind,randomised,placebo controlled trial of anakinra(Kineret),a recombinant interleukin 1 receptor antagonist,in patients with rheumatoid arthritis treated with background methotrexate.Ann Rheum Dis,2004,63(9):1062-1068.
36 Hui A,Kulkami GV,Hunter WL,et al.Paclitaxel selectively induces mitotic arrest and apoptosis in proliferating bovine synoviocytes.Arthritis Rheum,1997,40(6):1073-1084.
37 Firestein GS.Invasive fibroblast-like synoviocytes in rheumatoid arthritis:passive responders or transformed aggressors.Arthritis Rheum,1996,39(11):1781-1790.
38 Nakajima T,Aono H,Hasunuma T,et al.Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes.Arthritis Rheum,1995,38(4):485-491.
39 聂英坤,张凤山,孙凤琴.类风湿性关节炎的治疗现状与进展.临床荟萃,2004,19(2):119-120.
40 Tarner IH,H(a|¨)rle P,M(u|¨)ller-Ladner U,et al.The different stages of synovitis:acute vs chronic,early vs late and non-erosive vs erosive.Best Pract Res Clin Rheumatol,2005;19(1):19-35.
41 Evans CH,Ghivizzani SC,Kang R,et al.Gene therapy for rheumatic diseases.Arthritis Rheum,1999,42(1):1-16.
42 Adriaansen J,Vervoordeldonk MJ,Vanderbyl S,et al.A novel approach for gene therapy:engraftment of fibroblasts containing the artificial chromosome expression system at the site of inflammation.J Gene Med,2006,8(1):63-71.
43 Gould DJ,Bright C,Chernajovsky Y.Inhibition of established collagen-induced arthritis with a tumour necrosis factor-alpha inhibitor expressed from a selfcontained doxycycline regulated plasmid.Arthritis Res Ther,2004,6(2):R103-113.
44 Bakker AC,Van de Loo FA,Joosten LA,et al.C3-Tat/HIV-regulated intraarticular human interleukin-1 receptor antagonist gene therapy results in efficient inhibition of collagen- induced arthritis superior to cytomegalovirus-regulated expression of the same transgene. Arthritis Rheum, 2002,46(6):1661-1670.
45 Kim SH, Lechman ER, Kim S, et al. Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Mol Ther, 2002,6(5):591-600.
46 Van de Loo FA, Smeets RL, Van Den Berg WB. Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients? Arthritis Res Ther, 2004,6(5): 183-196.
47 Chernajovsky Y, Gould DJ, Podhajcer OL. Gene therapy for autoimmune diseases: quo vadis? Nat Rev Immunol, 2004,4(10): 800-811.
48 Tarner IH, Muller-Ladner U, Fathman CG Targeted gene therapy: frontiers in the development of 'smart drugs'. Trends Biotechnol,2004,22(6):304-310.
49 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1995,1(1):27-31.
50 Pandya NM, Dhalla NS, Santani DD. Angiogenesis—a new target for future therapy. Vascular Pharmacology, 2006,44(5):265-274.
51 Hanahan D, Folkman J.Patterns and emerging mechanisms of the angiogenic switch during rumorigenesis.Cell,1996,86(3):353-364.
52 Lowe PM, Lee ML, Jackson CJ, et al. The endothelium in psoriasis. Br J Dermatol, 1995,132(4): 497-505.
53 Koch AE, Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther, 2007, 9 (Suppl 2):S3.
54 Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun, 1989,161(2): 851-858.
55 Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science,1989,246(4935): 1306-1309.
56 Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J,1999,13(1): 9-22.
57 Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem, 1991,266(18):11947-11954.
58 Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell, 1993, 4(12):1317-1326.
59 Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med, 2005,9 (4):777-794.
60 Woolard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res, 2004, 64(21):7822-7835.
61 Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fins family. Oncogene,1990,5(4):519-524.
62 Terman BI, Carrion ME, Kovacs E, et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene, 1991,6(9): 1677-1683.
63 Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev, 2004,25(4):581-611.
64 Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature, 2005, 438 (7070): 967-974.
65 Pedram A, Razandi M, Levin ER. Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Ghem,1998,273(41):26722-26728.
66 Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem,1997,272(51): 32521-32527.
67 Qi JH, Claesson-Welsh L. VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp Cell Res,2001,263(1):173-182.
68 Rousseau S, Houle F, Landry J, et al. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene, 1997,15(18):2169-2177.
69 Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem,1998,273(46):30336-30343.
70 Ikeda M, Hosoda Y, Hirose S, et al. Expression of vascular endothelial growth factor isoforms and their receptors Fit-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol, 2000, 191(4):426-433.
71 Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res, 2002, 4 (suppl 3):S81-S90.
72 Maruotti N, Cantatore FP, Crivellato E, et al. Angiogenesis in rheumatoid arthritis. Histol Histopathol, 2006,21(5):557-566.
73 Thornton RD, Lane P, Borghaei RC, et al. Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J, 2000,350(Pt 1):307-312.
74 Berse B, Hunt JA, Diegel RJ, et al. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol, 1999,115(1):176-182.
75 Hernandez GL, Volpert OV, Iniguez MA, et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med,2001,193(5): 607-620.
76 陈飞虎.肿瘤血管生成抑制因子及Endostatin 研究进展.安徽医药,2003,7(1):5-7.
77 O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.Cell,1997,88(2):227-285.
78 Ding YH, Javaherian K, Lo KM, et al. Zine-dependant dimmers observed in crystals of human endostain. Proc Natl Acad Sci USA, 1998,95(18): 10443-10448.
79 Hohenester E, Sasaki T, Olsen BR, et al. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J, 1998,17(6): 1656-1664 .
80 Rehn M, Pihlajaniemi T. Alpha 1 (XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen. Proc Natl Acad Sci USA, 1994,91 (10):4234-4238.
81 Musso O, Rehn M, Saarela J, et al. Collagen XVIII is localized in sinusoids and basement membrane zones and expressed by hepatocytes and activated stellate cells in fibrotic human liver. Hepatology, 1998,28(1):98-107.
82 Dhanabal M, Ramchandran R, Volk R, et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res, 1999, 59(1): 189-197.
83 Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem, 1999,274 (17):11721-11726.
84 Hanai J, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D_1. J Biol Chem, 2002, 277(19): 16464-16469.
85 Kiselev SM, Lutsenko SV, Severin SE, et al. Tumor angiogenesis inhibitors. Biochemistry, 2003,68(5):497-513.
86 Nyberg P,Xie L,Kalluri R.Endogenous inhibitors of angiogenesis.Cancer Res,2005,65(10):3967-3979.
87 Lee SJ,Jang JW,Kim YM,et al.Endostatin binds to the catalytic domain of matrix metalloproteinase-2.FEBS Lett,2002,519(1-3):147-52.
88 Wickstrom SA,Veikkola T,Rehn M,et al.Endostatin-indused modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells.Cancer Res,2001,61(17):6511-6516.
89 MacDonald NJ,Shivers WY,Narum DL,et al.Endostatin binds tropomyosin.A potential modulator of the antitumor activtity of endostatin.J Biol Chem,2001,276(27):25190-25196.
90 Dixelius J,Larsson H,Sasaki T,et al.Endostatin-induced tyrosine kinase signaling through the adaptor protein regulates endothelial cell apoptosis.Blood,2000,95(11):3403-3411.
91 Matsuno H,Yudoh K,Uzuki M,et al.Treatment with the angiogenesis inhibitor endostatin:a novel therapy in rheumatoid arthritis.J Rheumatol,2002,29(5):890-895.
92 Yin G,Liu W,An P,et al.Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis.Mol Ther,2002,5(5 Pt 1):547-554.
93 夏丽娟,陈飞虎,黄学应,等.重组人内抑素对佐剂性关节炎大鼠滑膜组织血管内皮细胞生长因子表达的影响.中国临床药理学与治疗学,2006,11(7):760-763.
94 Nishioka K,Hasunuma T,Kato T,et al.Apoptosis in rheumatoid arthritis:a novel pathway in the regulation of synovial tissue.Arthritis Rheum,1998,41(1):1-9.
95 Pope RM.Apoptosis as a therapeutic tool in rheumatoid arthritis.Nat Rev Immunol,2002,2(7):527-535.
96 夏丽娟,陈飞虎,任斌,等.重组人内抑素对佐剂性关节炎大鼠滑膜细胞增殖及产生细胞因子的影响.中国药理学通报,2007,23(1):59-63.
97 Huang XY, Chen FH, Li J, et al. Mechanism of fibroblast-like synoviocyte apoptosis induced by recombinant human endostatin in rats with adjuvant arthritis. Anat Rec, 2008, May 28 [Epub ahead of print].
2 Firestein GS.Invasive fibroblast-like synoviocytes in rheumatoid arthritis:passive responders or transformed aggressors.Arthritis Rheum,1996,39(11):1781-1790.
3 Nishioka K,Hasunuma T,Kato T,et al.Apoptosis in rheumatoid arthritis:a novel pathway in the regulation of synovial tissue.Arthritis Rheum,1998,41(1):1-9.
4 Paleolog EM.Angiogenesis in rheumatoid arthritis.Arthritis Res,2002,4(suppl 3):S81-S90.
5 Paleolog EM,Miotla JM.Rheumatoid arthritis:A target for antiangiogenic therapy.Humana Press Inc,2001,8(6):129-149.
6 O'Reilly MS,Boehm T,Shing Y,et al.Endostatin:an endogenous inhibitor of angiogenesis and tumor growth.Cell,1997,88(2):227-285.
7 Dhanabal M,Ramchandran R,Waterman MJ,et al.Endostatin induces endothelial cell apoptosis.J Biol Chem,1999,274(17):11721-11726.
8 Cui R,Ohashi R,Takahashi F,et al.Signal transduction mediated by endostatin directly modulates cellular function of lung cancer cells in vitro.Cancer Sci,2007,98(6):830-837.
9 Wilson RF,Morse MA,Pei P,et al.Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells.Anticancer Res,2003,23(2B):1289-1295.
10 Hui A,Kulkami GV,Hunter WL,et al.Paclitaxel selectively induces mitotic arrest and apoptosis in proliferating bovine synoviocytes.Arthritis Rheum,1997,40(6):1073-1084.
11 Firestein GS.Evolving concepts of rheumatoid arthritis.Nature,2003,423(6937):356-361.
12 夏丽娟,陈飞虎,黄学应,等.重组人内抑素对佐剂性关节炎大鼠滑膜组织血管内皮细胞生长因子表达的影响.中国临床药理学与治疗学,2006,11(7):760-763.
13 夏丽娟,陈飞虎,任斌,等.重组人内抑素对佐剂性关节炎大鼠滑膜细胞增殖及产生细胞因子的影响.中国药理学通报,2007,23(1):59-63.
14 Huang XY,Chen FH,Li J,et al.Mechanism of fibroblast-like synoviocyte apoptosis induced by recombinant human endostatin in rats with adjuvant arthritis.Anat Rec,2008,May 28[Epub ahead of print].
15 李伟,张远强,刘新平,等.佐剂型类风湿关节炎模型改良与DDR2表达的研究.中国组织化学与细胞化学杂志,2003,12(1):89-93.
16 刘琼,王晨璐,方剑乔.类风湿性关节炎动物模型的研究进展.医学综述,2006,12(5):313-316.
17 陈柏松,徐玉东,钟淑琦,等.大鼠佐剂性关节炎模型的建立与评价.哈尔滨医科大学学报,2005,39(6):489-491.
18 Kim KM,Lee K,Hong YS,et al.Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cells.Exp Mol Med,2000,32(4):246-254.
19 Wang X.The expanding role of mitochondria in apoptosis.Genes Dev,2001,15(22):2922-2933.
20 Desagher S,Martinou JC.Mitochondria as the central control point of apoptosis.Trends Cell Biol,2000,10(9):369-377.
21 Ashkenazi A,Dixit VM.Death receptors:signaling and modulation.Science,1998,281(5381):1305-1308.
22 Sun XM,MacFarlane M,Zhuang J,et al.Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis.J Biol Chem,1999,274(8):5053-5060.
23 Nakamura K,Bossy-Wetzel E,Bums K,et al.Changes in endoplasmic reticulum luminal environment affect cell sensitivity to apoptosis.J Cell Biol,2000,150(4):731-740.
24 Thompson CB.Apoptosis in the pathogenesis and treatment of disease.Science,1995,267(5203):1456-1462.
25 Cutolo M,Sulli A,Barone A,et al.Sex hormones,proto-oncogene expression and apoptosis:their effects on rheumatoid synovial tissue.Clin Exp Rheumatol,1996,14(1):87-94.
26 Matsumoto S,Muller-Ladner U,Gay RE,et al.Ultrastructural demonstration of apoptosis,Fas and Bcl-2 expression of rheumatoid synovial fibroblasts.J Rheumatol,1996,23(8):1345-1352.
27 Nishioka K,Hasunuma T,Kato T,et al.Apoptosis in rheumatoid arthritis:a novel pathway in the regulation of synovial tissue.Arthritis Rheum,1998,41(1):1-9.
28 Pope RM.Apoptosis as a therapeutic tool in rheumatoid arthritis.Nat Rev Immunol,2002,2(7):527-535.
29 Firestein GS.Invasive fibroblast-like synoviocytes in rheumatoid arthritis:passive responders or transformed aggressors.Arthritis Rheum,1996,39(11):1781-1790.
30 刘继红,李卫东,林志彬.类风湿性关节炎细胞凋亡的研究现状.中国临床药理学和治疗学,2003,8(2):232-236.
31 Halestrap AP,Clarke SJ,Javadov SA.Mitochondria permeability transition pore opening during myocardial reperfusion—a target for cardioprotection.Cardiovasc Res,2004,61(3):372-385.
32 Murphy AN,Bredesen DE,Cortopassi G,et al.Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria.Proc Natl Accad Sci USA,1996,93(18):9893-9898.
33 Ichimiya M,Chang SH,Liu H,et al.Effect of Bcl-2 on oxidant-induced cell death and intracellular Ca~(2+) mobilization.Am J Physiol,1998,275(3 Pt 1):C832-C839.
34 Zhu L,Ling S,Yu XD,et al.Modulation of mitochondrial Ca~(2+) homeostasis by Bcl-2.J Biol Chem,1999,274(47):33267-33273.
35 Yang J,Liu X,Bhalla K,et al.Prevention of apoptosis by Bcl-2:release of cytochrome C from mitochondria blocked.Science,1997,275(5303):1129-1132.
36 Liu H,Pope RM.The role of apoptosis in rheumatoid arthritis.Curr Opin Pharmacol,2003,3(3):317-322.
37 Perlman H,Georganas C,Pagliari LJ,et al.Bcl-2 expression in synovial fibroblasts is essential for maintaining mitochondrial homeostasis and cell viability.J Immunol,2000,164(10):5227-5235.
38 Chen R,Valencia I,Zhong F,et al.Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1,4,5-trisphosphate.J Cell Biol,2004,166(2):193-203.
39 张兴民,蒋明,郑德先,等.类风湿关节炎病人滑膜细胞增生与fas和bcl-2基因的表达.中华医学杂志,1998,78(3):175-178.
40 Sionov RV,Haupt Y.Apoptosis by p53:mechanisms,regulation,and clinical implications.Springer Semin Immunopathol,1998,19(3):345-362.
41 Tak PP,Zvaifler NJ,Green DR,et al.Rheumatoid arthritis and p53:how oxidative stress might Alter the course of inflammation diseases.Immunol Today,2000,21(2):78-82.
42 Tak PP,Klapwijk MS,Broersen SFM,et al.Apoptosis and p53 expression in rat adjuvant arthritis.Arthritis Res,2000,2(3):229-235.
43 Yamanishi Y,Boyle DL,Pinkoski MJ,et al.Regulation of joint destruction and inflammation by p53 in collagen-induced-arthritis.Am J Pathol,2002,160(1):123-130.
44 Yue L,Shen YX,Feng LJ,et al.Blockage of the formation of new blood vessels by recombinant human endostatin contributes to the regression of rat adjuvant arthritis.Eur J Pharmacol,2007,567:166-170.
45 Krammer PH.CD95's deadly mission in the immune system.Nature,2000,407(6805):789-795.
46 Itoh K,Hase H,Kojima H,et al.Central role of mitochondria and p53 in Fas- mediated apoptosis of rheumatoid synovial fibroblasts.Rheumatology,2004,43(3):277-285.
47 Chou CT,Yang JS,Lee MR.Apoptosis in rheumatoid arthritis—expression of Fas,Fas-L,p53,and Bcl-2 in rheumatoid synovial tissues.J Pathol,2001,193(1):110-116.
48 Lech K,Andeson K,Brent K.DNA-bound fos proteins activate transcription in yeast.Cell,1988,52(2):179-184.
49 Smeyne RJ,Vendrell MV,Hayward M,et al.Continuous c-fos expression precedes programmed cell death in vivo.Nature,1993,363(13):166-169
50 Wagstaff SC,Bowler WB,Gallagher JA,et al.Extracellular ATP activates multiple signaling pathways and potentiates growth factor-induced c-fos gene expression in MCF-7 breast cancer cells.Carcinogenesis,2000,21(12):2175-2181.
51 林华,魏海燕,蒋青,等.原发性骨质疏松骨组织c-fos,c-jun和p53基因的表达.中国骨肿瘤骨病,2003,2(6):368-371.
52 Leppa S,Bohmann D.Diverse functions of JNK signaling and c-Jun in stress response and apoptosis.Oncogene,1999,18(45):6158-6162.
53 Shaulian E,Karin M.AP-1 as a regulator of cell life and death.Nat Cell Biol,2002,4(5):E131-136.
54 Bossy-Wetzel E,Bakiri L,Yaniv M.Induction of apoptosis by the transcription factor c-Jun.Embo J,1997,16(7):1695-1709.
55 Kolbus A,Herr I,Schreiber M,et al.c-Jun-dependent CD95-L expression is a ratelimiting step in the induction of apoptosis by alkylating agents.Mol Cell Biol,2000,20(2):575-582.
56 Cheung NS,Carroll FY,Larm JA,et al.Kainat-induced apoptosis,correlates with c-jun activation in cultured cerebellar granile cells.J Neutosci Res,1998,52(1):69-82
57 Baldwin AS.The NF-κB,IκB proteins new discoveries and insights.Annu Rev Immunol,1996,14(2):649-683.
58 黄培林,朱世能,陆世伦.NFκB,IκB与肿瘤细胞凋亡.实用癌症杂志,2001,16(1):103-104.
59 Han Z,Boyle DL,Manning AM,et al.AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis.Autoimmunity,1998,28(4):197-208.
60 Sioud M,Mellbye O,Forre O.Analysis of the NF-κB p65 subunit,Fas antigen,Fas ligand and Bcl-2-related proteins in the synovium of RA and polyarticular JRA.Clin Exp Rheumatol,1998,16(2):125-134.
61 Chen F,Castranova V,Shi X,et al.New insights into the role of nuclear factorkappaB,a ubiquitous transcription factor in the initiation of diseases.Clin Chem,1999,45(1):7-17.
62 Campbell IK,Gerondakis S,O'Donnell K,et al.Distinct roles for the NF-kappaB1(p50) and c-Rel transcription factors in inflammatory arthritis.J Clin Invest,2000105(12):1799-1806.
63 韩飞,尤欣,唐福林.核因子κB在类风湿关节炎滑膜组织中的表达及意义.中华风湿病学杂志,2004,8(3):143-146.
64 Handel ML,Mcmorrow LB,Gravallese EM.NF-kappa B in rheumatoid synovium:location of p50 and p65.Arthritis Rheum,1995,38(12):1762-1770.
65 PoterAG,Janieke RU.Emerging roles of caspase-3 in apoptosis.Cell Death Differ,1999,6(2):99-104.
66 Saikumar P,Dong Z,Mikhailov V,et al.Apoptosis:definition,mechanism,and relevance to disease.Am J Med,1999,107(5):489-506.
67 Hengartner MO.The biochemistry of apoptosis.Nature,2000,407(6805):770-776
68 Cohen GM.Caspases:the executioners of apoptosis.Biochem J,1997,326(1):1-16.
69 Yeh JY,Hsu SC,Han SH,et al.Mitogen-activated protein kinase kinase antagonized fas-associated Death Domain Protein-mediated apoptosis by induced FLICE-inhibitory protein expression.J Exp Med,1998,188(10):1795-1802.
70 刘景生主编.细胞信息与调控(第二版).北京:中国协和医科大学出版社.2004
71 唐海林,苏琦.钙离子信号与细胞凋亡关系的研究进展.南华大学学报(医学版),2006,34(5):663-666.
72 曾娅莉,黄文芳,卢贤瑜.细胞凋亡时线粒体钙离子信号调节因素研究进展.国际检验医学杂志,2006,27(6):543-545
73 Cho MR,Marler JP,Thatte HS,et al.Contorl if calcium entry in human fiborblasts by ferquency-dependent electrical stimulation.Front Biosci,2002,7(1):1-8.
74 史绢,李继硕.细胞内钙成像和钙测定的基本原理及应用.神经解剖学杂志,2006,22(4):455-462.
75 孙玮,路菊,潘峰,等.牛磺酸对乳鼠心肌细胞内钙浓度的影响.氨基酸和生物资源,2007,29(3):60-62.
76 李谨,蒋春梅,徐艳,等.硝苯地平对人牙龈成纤维细胞内Ca~(2+)含量影响的激光共聚焦显微观察.口腔医学研究,2006,22(5):495-497.
77 Sun Y,Vernier PT,Behrend M,et al.Fluorescence microscopy imaging of electroperturbation in mammalian cells.J Biomed Opt,2006,11(2):124-127.
78 孙文武,胡芬,杨文修.热和低渗刺激活化胞外Ca~(2+)内流机制升高大鼠滑膜细胞[Ca~(2+)]i.科学通报,2007,52(23):2752-2758.
79 Parekh AB,Reinhold P.Store depletion and calcium influx.Physiol Rev,1997,77(4):901-930
80 郭静,蒲咏梅,张东才.钙离子信号与细胞凋亡.生物物理学报,2005,21(1):1-18.
81 Bernardi P.Mitochondrial transport of cations:channels,exchangers,and permeability transition.Physiol Rev,1999,79(4):1127-1155.
82 Missiaen L,Robberecht W,Van Den Bosch L et al.Abnormal intracellular Ca~(2+)homeostasis and disease.Cell Calcium,2000;28(1):1-21.
83 Van den Heuvel,S.Cell-cycle regulation.Worm Book,2005,Sep21:1-16.
84 Branzei D,Foiani M.Regulation of DNA repair throughout the cell cycle.Nat Rev Mol Cell Biol,2008,9(4):297-308.
85 Yang K,Hitomi M,Stacey DW.Variations in cyclin D_1 levels through the cell cycle determine the proliferative fate of a cell.Cell Div,2006,1:32.
86 刘巧红,沈凌汛,滕云.类风湿关节炎滑膜细胞的增殖及细胞周期的研究.临床内科杂志,2004,21(12):814-816.
87 Xu R,Du P,Fan JJ,et al.High-level exepression and secretion of recombinant mouse endostatin by Escherichia coil.Protein Expr Purif,2002,24(3):453-459.
88 Liu G.;Lozano G.p21 Stability:linking chaperones to cell cycle checkpoint.Cancer Cell,2005,7(2):113-114.
89 He G,Siddik ZH,Huang Z,et al.Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities.Oncogene,2005,24(18):2929-2943.
90 Seville LL,Shah N,Westwell AD,et al.Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer.Curr Cancer Drug Targets,2005,5(3):159-170
91 Barboule N,Mazars P,Baldin V,et al.Expression of p21 WAF_1/CIP_1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma.Int J Cancer,1995,63(5):611-615.
92 Baretton GB,Klenk U,Dieold J,et al.Proliferation and apoptosis associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy:prognostic significance of p21 WAF_1/CIP_1 expression.Br J Cancer,1999,80(3-4):546-555.
93 周美英,谢立香.子宫内膜癌P21CIP1/WAF1和PCNA表达的研究.中国妇幼保健,2007,22(14):1991-1993.
94 朱江军,叶招明.骨肉瘤G1细胞周期调控因子研究进展.国际骨科学杂志,2006,27(6):344-347.
95 Hanai J,Dhanabal M,Karumanchi SA,et al.Endostatin causes G1 arrest of endothelial cells through inhibition of cyclinD_1.J Biol Chem,2002,277(19):16464- 16469.
96 Sakayama K,Fujibuchi T,Kidani T,et al.proliferative activity of osteosarcoma cells:comparison of osteoblastic and nonosteoblastic regions.J Orthop Sci,2003,8(5):678-682.
97 宋楠萌,桑建利,徐恒.增殖细胞核抗原(PCNA)的分子结构及其生物学功能研究进展.自然科学进展,2006,16(10):1201-1209.
1 吴丽,魏伟.类风湿关节炎中血管生成的分子机制.中国药理学通报,2004,20(10):1098-10102.
2 Paleolog EM,Miotla JM.Rheumatoid arthritis:A target for antiangiogenic therapy.Humana Press Inc,2001,8(6):129-149.
3 Wollhim FA.New function for COX-2 in health and disease.Arthritis Research,1999,1(1):45-49.
4 董怡,赵岩.抗风湿新药的概述.中国新药杂志,2001,10(1):10-14.
5 刘雁,李志军.非甾体抗炎药物的药理及临床应用进展.中国医院药学杂志,2000,20(12):748-750.
6 刘扬渝,董碧蓉.类风湿性关节炎药物治疗及策略进展.现代临床医学,2006,32(1):74-76.
7 Vane JR.Towards a better aspirin.Nature,1994,367(6460):215-216.
8 Vane JR,Botting RM.Mechanism of action of anti-inflammatory drugs.Scand J Rheumatol,1996,102(Suppl):9-21.
9 Cannon G,Caldwell J,Holt P,et al.MK-0966,a specific COX-2 inhibitor,has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis in a 26 week controlled clinical trial.Arthritis Rheum,1998,41(Suppl 9):196.
10 Geis GS,Stead H,Morant S,et al.Efficacy and safety of celecoxib,a specific COX-2 inhibitor,in patients with rheumatioid arthritis.Arthritis Rheum,1998,41(Suppl 9):316.
11 刘肖平.特异性COX-2抑制剂临床应用安全性新动态.实用疼痛学杂志,2005,1(2):66-68.
12 Scott DL.Advances in the medical management of rheumatoid arthritis.Hosp Med,2002,63(5):294-297.
13 邱一华,骆合德.类风湿性关节炎的药物治疗进展.中国综合临床,2001,17(7): 485-487.
14 Conn DL,Lim SS.New role for an old friend:prednisone is a disease-modifying agent in early rheumatoid arthritis.Curr Opin Rheumatol,2003,15(3):193-196.
15 曾应馀,刘建平.类风湿关节炎的药物治疗进展.中华内科杂志,1997,36(4):273-275.
16 Tsakonas E,Fitzgerald AA,Fitzcharles MA,et a.l Conse-quences of delayed therapy with second-line agents in rheumatoid arthritis:a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis study.J Rheumatol,2000,27(3):623-629.
17 Lard LR,Visser H,Speyer I,et al.Early versus delayed treatment in patients with recent-onset rheumatoid arthritis:comparison of two cohorts who received different treatment strategies[J].Am J Med,2001,111(6):446-451
18 Kremer JM.Methotrexate and emerging therapies.Rheum Dis Clin North Am,1998,24(3):651-658
19 Aringer M,Graninger WB.Treating rheumatoid arthritis with new disease modifying drugs[J].Acta Med Austriaca,2002,29(1):33-35.
20 Yocum DE,Solinger AM,Tesser J,et al.Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis:results of a phase Ⅰ,single dose,dose escalating trial.J Rheumatol,1998,25(7):1257-1262.
21 Vandenbark AA,Morgan E,Bartholomew R,et al.TCR peptide therapy in human autoimmune diseases[J].Neurochem Res,2001,26(6):713-730.
22 Moreland LW,Morgan EE,Adamson TC,et al.T cell receptor peptide vaccination in rheumatoid arthritis:a placebo-controlled trial using a combination of Vbeta_3,Vbeta_(14),and Vbeta_(17) peptides.Arthritis Rheum.1998,41(11):1919-1929.
23 张新梅,赵文明.类风湿性关节炎免疫治疗的研究进展.医学综述,2004,10(2):115-117.
24 王韫秀,王洪涛,刘亭威.类风湿性关节炎药物治疗新进展.实用药物与临床,2006,(6)4:253-254.
25 Walsh NC,Gravallese EM.Bone loss in inflammatory arthritis:mechanisms and treatment strategies.Curr Opin Rheumatol,2004,16(4):419-427.
26 Tak PP,Bresnihan B.The pathogenesis and prevention of joint damage in rheumatoid arthritis:advances from synovial biopsy and tissue analysis.Arthritis Rheum,2000,43(12):2619-2633.
27 Vervoordeldonk MJ,Tak PP.Cytokines in rheumatoid arthritis.Curr Rheumatol Rep,2002,4(3):208-217.
28 Tak PP,Smeets TJ,Daha MR,et al.Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity.Arthritis Rheum,1997,40(2):217-225.
29 Olsen NJ,Stein CM.New drugs for rheumatoid arthritis.N Engl J Med,2004,350(21):2167-2179.
30 刘彧,韩星海,孟济明.生物制剂在类风湿关节炎治疗中的应用.中华风湿病学杂志,2003,7(5):300-302.
31 Adriaansen J,Vervoordeldonk MJ,Tak PP.Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis:innovative vectors and therapeutic genes.Rheumatology(Oxford),2006,45(6):656-668.
32 牛丽娟,张立生.类风湿性关节炎药物治疗的进展.实用疼痛学杂志,2006,2(2):106-110.
33 Flendrie M,Creemers MC,Welsing PM,et al.The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis;a longitudinal observational study.Rheumatology (Oxford),2005,44(4):472-478.
34 Hamilton K,Clair EW.Tumour necrosis factor-alpha blockade:a new era for effective management of rheumatoid arthritis.Expert Opin Pharmacother,2000, 1(5):1041-1052.
35 Cohen SB,Moreland LW,Cush JJ,et al.A multicentre,double blind,randomised,placebo controlled trial of anakinra(Kineret),a recombinant interleukin 1 receptor antagonist,in patients with rheumatoid arthritis treated with background methotrexate.Ann Rheum Dis,2004,63(9):1062-1068.
36 Hui A,Kulkami GV,Hunter WL,et al.Paclitaxel selectively induces mitotic arrest and apoptosis in proliferating bovine synoviocytes.Arthritis Rheum,1997,40(6):1073-1084.
37 Firestein GS.Invasive fibroblast-like synoviocytes in rheumatoid arthritis:passive responders or transformed aggressors.Arthritis Rheum,1996,39(11):1781-1790.
38 Nakajima T,Aono H,Hasunuma T,et al.Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes.Arthritis Rheum,1995,38(4):485-491.
39 聂英坤,张凤山,孙凤琴.类风湿性关节炎的治疗现状与进展.临床荟萃,2004,19(2):119-120.
40 Tarner IH,H(a|¨)rle P,M(u|¨)ller-Ladner U,et al.The different stages of synovitis:acute vs chronic,early vs late and non-erosive vs erosive.Best Pract Res Clin Rheumatol,2005;19(1):19-35.
41 Evans CH,Ghivizzani SC,Kang R,et al.Gene therapy for rheumatic diseases.Arthritis Rheum,1999,42(1):1-16.
42 Adriaansen J,Vervoordeldonk MJ,Vanderbyl S,et al.A novel approach for gene therapy:engraftment of fibroblasts containing the artificial chromosome expression system at the site of inflammation.J Gene Med,2006,8(1):63-71.
43 Gould DJ,Bright C,Chernajovsky Y.Inhibition of established collagen-induced arthritis with a tumour necrosis factor-alpha inhibitor expressed from a selfcontained doxycycline regulated plasmid.Arthritis Res Ther,2004,6(2):R103-113.
44 Bakker AC,Van de Loo FA,Joosten LA,et al.C3-Tat/HIV-regulated intraarticular human interleukin-1 receptor antagonist gene therapy results in efficient inhibition of collagen- induced arthritis superior to cytomegalovirus-regulated expression of the same transgene. Arthritis Rheum, 2002,46(6):1661-1670.
45 Kim SH, Lechman ER, Kim S, et al. Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Mol Ther, 2002,6(5):591-600.
46 Van de Loo FA, Smeets RL, Van Den Berg WB. Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients? Arthritis Res Ther, 2004,6(5): 183-196.
47 Chernajovsky Y, Gould DJ, Podhajcer OL. Gene therapy for autoimmune diseases: quo vadis? Nat Rev Immunol, 2004,4(10): 800-811.
48 Tarner IH, Muller-Ladner U, Fathman CG Targeted gene therapy: frontiers in the development of 'smart drugs'. Trends Biotechnol,2004,22(6):304-310.
49 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1995,1(1):27-31.
50 Pandya NM, Dhalla NS, Santani DD. Angiogenesis—a new target for future therapy. Vascular Pharmacology, 2006,44(5):265-274.
51 Hanahan D, Folkman J.Patterns and emerging mechanisms of the angiogenic switch during rumorigenesis.Cell,1996,86(3):353-364.
52 Lowe PM, Lee ML, Jackson CJ, et al. The endothelium in psoriasis. Br J Dermatol, 1995,132(4): 497-505.
53 Koch AE, Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther, 2007, 9 (Suppl 2):S3.
54 Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun, 1989,161(2): 851-858.
55 Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science,1989,246(4935): 1306-1309.
56 Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J,1999,13(1): 9-22.
57 Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem, 1991,266(18):11947-11954.
58 Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell, 1993, 4(12):1317-1326.
59 Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med, 2005,9 (4):777-794.
60 Woolard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res, 2004, 64(21):7822-7835.
61 Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fins family. Oncogene,1990,5(4):519-524.
62 Terman BI, Carrion ME, Kovacs E, et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene, 1991,6(9): 1677-1683.
63 Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev, 2004,25(4):581-611.
64 Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature, 2005, 438 (7070): 967-974.
65 Pedram A, Razandi M, Levin ER. Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Ghem,1998,273(41):26722-26728.
66 Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem,1997,272(51): 32521-32527.
67 Qi JH, Claesson-Welsh L. VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp Cell Res,2001,263(1):173-182.
68 Rousseau S, Houle F, Landry J, et al. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene, 1997,15(18):2169-2177.
69 Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem,1998,273(46):30336-30343.
70 Ikeda M, Hosoda Y, Hirose S, et al. Expression of vascular endothelial growth factor isoforms and their receptors Fit-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol, 2000, 191(4):426-433.
71 Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res, 2002, 4 (suppl 3):S81-S90.
72 Maruotti N, Cantatore FP, Crivellato E, et al. Angiogenesis in rheumatoid arthritis. Histol Histopathol, 2006,21(5):557-566.
73 Thornton RD, Lane P, Borghaei RC, et al. Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J, 2000,350(Pt 1):307-312.
74 Berse B, Hunt JA, Diegel RJ, et al. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol, 1999,115(1):176-182.
75 Hernandez GL, Volpert OV, Iniguez MA, et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med,2001,193(5): 607-620.
76 陈飞虎.肿瘤血管生成抑制因子及Endostatin 研究进展.安徽医药,2003,7(1):5-7.
77 O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.Cell,1997,88(2):227-285.
78 Ding YH, Javaherian K, Lo KM, et al. Zine-dependant dimmers observed in crystals of human endostain. Proc Natl Acad Sci USA, 1998,95(18): 10443-10448.
79 Hohenester E, Sasaki T, Olsen BR, et al. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J, 1998,17(6): 1656-1664 .
80 Rehn M, Pihlajaniemi T. Alpha 1 (XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen. Proc Natl Acad Sci USA, 1994,91 (10):4234-4238.
81 Musso O, Rehn M, Saarela J, et al. Collagen XVIII is localized in sinusoids and basement membrane zones and expressed by hepatocytes and activated stellate cells in fibrotic human liver. Hepatology, 1998,28(1):98-107.
82 Dhanabal M, Ramchandran R, Volk R, et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res, 1999, 59(1): 189-197.
83 Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem, 1999,274 (17):11721-11726.
84 Hanai J, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D_1. J Biol Chem, 2002, 277(19): 16464-16469.
85 Kiselev SM, Lutsenko SV, Severin SE, et al. Tumor angiogenesis inhibitors. Biochemistry, 2003,68(5):497-513.
86 Nyberg P,Xie L,Kalluri R.Endogenous inhibitors of angiogenesis.Cancer Res,2005,65(10):3967-3979.
87 Lee SJ,Jang JW,Kim YM,et al.Endostatin binds to the catalytic domain of matrix metalloproteinase-2.FEBS Lett,2002,519(1-3):147-52.
88 Wickstrom SA,Veikkola T,Rehn M,et al.Endostatin-indused modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells.Cancer Res,2001,61(17):6511-6516.
89 MacDonald NJ,Shivers WY,Narum DL,et al.Endostatin binds tropomyosin.A potential modulator of the antitumor activtity of endostatin.J Biol Chem,2001,276(27):25190-25196.
90 Dixelius J,Larsson H,Sasaki T,et al.Endostatin-induced tyrosine kinase signaling through the adaptor protein regulates endothelial cell apoptosis.Blood,2000,95(11):3403-3411.
91 Matsuno H,Yudoh K,Uzuki M,et al.Treatment with the angiogenesis inhibitor endostatin:a novel therapy in rheumatoid arthritis.J Rheumatol,2002,29(5):890-895.
92 Yin G,Liu W,An P,et al.Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis.Mol Ther,2002,5(5 Pt 1):547-554.
93 夏丽娟,陈飞虎,黄学应,等.重组人内抑素对佐剂性关节炎大鼠滑膜组织血管内皮细胞生长因子表达的影响.中国临床药理学与治疗学,2006,11(7):760-763.
94 Nishioka K,Hasunuma T,Kato T,et al.Apoptosis in rheumatoid arthritis:a novel pathway in the regulation of synovial tissue.Arthritis Rheum,1998,41(1):1-9.
95 Pope RM.Apoptosis as a therapeutic tool in rheumatoid arthritis.Nat Rev Immunol,2002,2(7):527-535.
96 夏丽娟,陈飞虎,任斌,等.重组人内抑素对佐剂性关节炎大鼠滑膜细胞增殖及产生细胞因子的影响.中国药理学通报,2007,23(1):59-63.
97 Huang XY, Chen FH, Li J, et al. Mechanism of fibroblast-like synoviocyte apoptosis induced by recombinant human endostatin in rats with adjuvant arthritis. Anat Rec, 2008, May 28 [Epub ahead of print].